Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cesamet for the Prevention of Postoperative Nausea and Vomiting
NCT02115529Phase 2Completed
- Sponsor
- Unity Health Toronto
- Start
- Apr 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in postoperative nausea and vomiting (PONV) comparing Cesamet (nabilone) with Placebo (2 arms). Primary endpoint: Incidence of postoperative nausea and/or vomiting at 2 hours. Started Apr 2014; status: completed.
02
Drugs
nabilone
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT02115529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02115529.